Jason Luke
Overview
Explore the profile of Jason Luke including associated specialties, affiliations and a list of published articles.
Author names and details appear as published. Due to indexing inconsistencies, multiple individuals may share a name, and a single author may have variations. MedLuna displays this data as publicly available, without modification or verification
Snapshot
Snapshot
Articles
7
Citations
441
Followers
0
Related Specialties
Related Specialties
Top 10 Co-Authors
Top 10 Co-Authors
Published In
Affiliations
Affiliations
Soon will be listed here.
Recent Articles
1.
Lehrich B, Monga S, Lehrich B, Delgado E, Delgado E, Yasaka T, et al.
Res Sq
. 2024 Dec;
PMID: 39711542
First-line immune checkpoint inhibitor (ICI) combinations show responses in subsets of hepatocellular carcinoma (HCC) patients. Nearly half of HCCs are Wnt-active with mutations in (encoding for β-catenin), , or ,...
2.
Yushak M, Mehnert J, Luke J, Poklepovic A
Am Soc Clin Oncol Educ Book
. 2019 May;
39:e207-e211.
PMID: 31099653
Over the last decade, several therapies, including both targeted and immune checkpoint inhibitors, have dramatically changed the treatment landscape for patients with metastatic melanoma. These same therapies are now being...
3.
Berry S, Giraldo N, Nguyen P, Green B, Xu H, Ogurtsova A, et al.
J Immunother Cancer
. 2019 Feb;
7(1):46.
PMID: 30760319
After publication of this supplement [1, 2], it was brought to our attention that due to an error authors were missing in the following abstracts. This has now been included...
4.
Ankeny J, Labadie B, Luke J, Hsueh E, Messina J, Zager J
Clin Exp Metastasis
. 2018 May;
35(5-6):487-493.
PMID: 29722000
Melanoma is an aggressive cutaneous malignancy with rapidly rising incidence. Diagnosis of controversial melanocytic lesions, correct prognostication of patients, selection of appropriate adjuvant and systemic therapies, and prediction of response...
5.
Shuk E, Shoushtari A, Luke J, Postow M, Callahan M, Harding J, et al.
Support Care Cancer
. 2017 Mar;
25(7):2155-2167.
PMID: 28247127
Purpose: Ipilimumab was the first FDA-approved agent for advanced melanoma to improve survival and represents a paradigm shift in melanoma and cancer treatment. Its unique toxicity profile and kinetics of...
6.
Massard C, Gordon M, Sharma S, Rafii S, Wainberg Z, Luke J, et al.
J Clin Oncol
. 2016 Jun;
34(26):3119-25.
PMID: 27269937
Purpose: To investigate the safety and efficacy of durvalumab, a human monoclonal antibody that binds programmed cell death ligand-1 (PD-L1), and the role of PD-L1 expression on clinical response in...
7.
Luke J, Mirkin J, Bach P
J Oncol Pract
. 2012 Mar;
7(6):402-4.
PMID: 22379427
The authors discuss the current state of Medicare reimbursement policy and outline their recently published model to link improvements in the quality of cancer care to reductions in overall cost.